Jochen Willner

Medicine · Health Sciences

16h-index1.4kcitations63works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Diagnosis and Treatment(18), Lung Cancer Treatments and Mutations(18), Advanced Radiotherapy Techniques(15), Breast Cancer Treatment Studies(11), Cancer Diagnosis and Treatment(8)

Publications63 total

Impact of target volume and dose concepts on the outcomes of prostate cancer patients treated with stereotactic body radiotherapy for spinal metastases - a European multicenter cohort study
Universität Zürich, ZORA·2026Open Access
Impact of target volume and dose concepts on the outcomes of prostate cancer patients treated with stereotactic body radiotherapy for spinal metastases − a European multicenter cohort study
Radiotherapy and Oncology·2025Open Access
Impact of Target Volume and Dose Concepts on the Outcomes of Prostate Cancer Patients Treated with Stereotactic Body Radiotherapy for Spinal Metastases - A European Multicenter Cohort Study
SSRN Electronic Journal·2025Open Access
Strukturelle, prozedurale und personelle Voraussetzung für die Erbringung radioonkologischer und strahlentherapeutischer Leistungen 2023 in Deutschland – ein Positionspapier der Deutschen Gesellschaft für Radioonkologie (DEGRO)
Strahlentherapie und Onkologie·2023· 6 citedOpen Access
Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities
Strahlentherapie und Onkologie·2023· 14 citedOpen Access
Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose
Strahlentherapie und Onkologie·2021· 11 citedOpen Access
OC-0416: Can a consistent dose to the target volume in SBRT be obtained by prescribing on the mean ITV dose?
Radiotherapy and Oncology·2018Open Access
Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer
Strahlentherapie und Onkologie·2013· 11 cited
Concurrent Chemoradiation Therapy With Docetaxel/Cisplatin Followed by Docetaxel Consolidation Therapy in Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer: Results of a Phase I Study
Clinical Lung Cancer·2010· 4 cited
Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy
Strahlentherapie und Onkologie·2009· 3 cited
2. Surgical treatment for recurrent gynecologic malignancy(Session 2 Oncology,Meet the Expert) :
日本産科婦人科學會雜誌·2009
Unternehmen in regionaler Verantwortung
uwf UmweltWirtschaftsForum·2007
Patterns of Care in the Radiotherapy of Prostate Cancer in Northern Bavaria 1998–2000
Strahlentherapie und Onkologie·2007· 11 cited
Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group
Journal of Clinical Oncology·2006· 135 citedOpen Access
Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1α (HIF-1α)
Cancer Letters·2005· 73 cited
Is survival following post-operative radiotherapy in pN1-non-small cell lung cancer reduced? Results of a multivariate analysis
Oncology Reports·2004· 1 cited
A phase I study of concurrent chemoradiotherapy with docetaxel-cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology·2004· 1 cited
A phase I study of concurrent chemoradiotherapy with docetaxel-cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology·2004
Induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): Update of CT/RT 99/97
Journal of Clinical Oncology·2004· 24 cited
Recurrent Rectal Cancer within the Pelvis
Strahlentherapie und Onkologie·2004· 22 cited
page 1 of 4Next →

Frequent Co-authors

Michael Flentje(26), Oliver Kölbl(9), L. Pfreundner(7), W Bohndorf(6), Kurt Baier(5), Rudolf M. Huber(5), Klaus Bratengeier(5), Dirk Vordermark(4), I Kiricuţă(4), Ion Christian Kiricuta(3), Michael Schmidt(3), H. Gosse(3), Florian Hoppe(3), Astrid Borgmeier(3), Matthias Gückenberger(3), Ludwig Keilholz(3), Ekaterini Caragiani(2), Kurt Ulm(2), K. Schwager(2), F. Schwab(2)